No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
AXSM241220C80000
- 12.38
- -0.07-0.56%
15min DelayClose Dec 20 16:00 ET
12.38High12.38Low
12.38Open12.45Pre Close1 Volume256 Open Interest80.00Strike Price1.24KTurnover0.00%IV1.82%PremiumDec 20, 2024Expiry Date10.73Intrinsic Value100Multiplier-1DDays to Expiry1.65Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma8.40Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Announces Target Price $124
Analysts' Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), Zymeworks (ZYME) and Axsome Therapeutics (AXSM)
Positive Outlook for Axsome Therapeutics: Buy Rating Backed by Promising AXS-05 Prospects
Axsome Therapeutics: Promising Growth Trajectory Justifies Buy Rating Amidst Auvelity's Commercial Success
Express News | Axsome Therapeutics Inc : Mizuho Raises Target Price to $124 From $106
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125